Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 31;8(8):CD006119.
doi: 10.1002/14651858.CD006119.pub4.

Evaluation of follow-up strategies for women with epithelial ovarian cancer following completion of primary treatment

Georgia Zachou  1 , Fatima El-Khouly  2 , James Dilley  1
Affiliations

Evaluation of follow-up strategies for women with epithelial ovarian cancer following completion of primary treatment

Georgia Zachou et al. Cochrane Database Syst Rev. .

Abstract

Background: This is an update of a previous Cochrane Review, last updated in 2014. Ovarian cancer is the eighth most common cancer and seventh most common cause of death due to cancer in women worldwide. Traditionally, most women who have been treated for cancer undergo long-term follow-up in secondary care. However, it has been suggested that the use of routine review may not be effective in improving survival, or health-related quality of life (HRQOL), or relieving anxiety. In addition, traditional follow-up may not be cost-effective.

Objectives: To compare the potential effects of different strategies of follow-up in women with epithelial ovarian cancer, following completion of primary treatment.

Search methods: For this update, we searched the Cochrane Gynaecological Cancer Group Trials Register, CENTRAL 2022, Issue 11, MEDLINE, and Embase from August 2013 to November 2022. We also searched review articles and contacted experts in the field.

Selection criteria: All randomised controlled trials (RCTs) that evaluated follow-up strategies for women with epithelial ovarian cancer following completion of primary treatment.

Data collection and analysis: We followed standard Cochrane methodology. Two review authors independently selected potentially relevant trials, extracted data, and assessed risk of bias. They compared results, and resolved disagreements by discussion. We assessed the certainty of evidence, using the GRADE approach, for the outcomes of interest: overall survival (OS), health-related quality of life (HRQOL), psychological effects, and cost analysis.

Main results: For this update, we included one new RCT, including 112 women with ovarian, fallopian tube, or peritoneal cancer, who had completed primary treatment by surgery, with or without chemotherapy. This study reported the effect of individualised, i.e. individually tailored, nurse-led follow-up versus conventional medical follow-up on HRQOL, psychological outcomes, and cost-analysis. Individualised follow-up improved HRQOL in one of the two scales, with a decrease in mean difference (MD) in the QLQ-C30 discomfort scale following 12 months of individualised treatment compared to 12 months of conventional treatment (MD -5.76 points, 95% confidence interval (CI) -10.92 to -0.60; 1 study, 112 participants; low-certainty evidence; minimal important difference 4 to 10 points). There may be little or no difference in the other HRQOL scale (QLQ-Ov28, MD -0.97 points, 95% CI -2.57 to 0.63; 1 study, 112 participants: low-certainty evidence); psychological outcome, measured with the hospital anxiety and depression scale (HADS; MD 0.10 point, 95% CI -0.81 to 1.02; 1 study, 112 participants: low-certainty evidence), or cost analysis (MD -GBP 695.00, 95% CI -1467.23 to 77.23; 1 study, 112 participants: moderate-certainty evidence). Our previous review included one RCT, with 529 women in a confirmed remission, with normal CA125 concentration and no radiological evidence of disease, after surgery and first-line chemotherapy for ovarian cancer. This study evaluated immediate treatment of ovarian cancer relapse following a rise of serum CA125 levels versus delaying treatment until symptoms developed for OS, and HRQOL. There was little or no difference in OS between the immediate and delayed arms after a median follow-up of 56.9 months (unadjusted hazard ratio (HR) 0.98, 95% CI 0.80 to 1.20; 1 study, 529 participants; moderate-certainty evidence). Time from randomisation to first deterioration in global health score or death was shorter in the immediate treatment group than in the delayed treatment group (HR 0.71, 95% CI 0.58 to 0.88).

Authors' conclusions: Limited evidence from one trial suggests that routine surveillance with CA125 in asymptomatic women and treatment at CA125-defined relapse does not seem to offer survival advantage when compared to treatment at symptomatic relapse. However, this study pre-dates the use of PARPi maintenance treatment and the increased use of secondary cytoreductive surgery, so the results may be limited in their applicability to current practice. Limited evidence from one trial suggests that individualised nurse-led follow-up may improve HRQOL in women with ovarian cancer following completion of primary treatment. Large RCTs are needed to compare different types of follow-up, looking at survival, HRQOL, psychological effects, and cost as outcomes.

PubMed Disclaimer

Conflict of interest statement

Georgia Zachou: none known James Dilley: none known Fatima El‐Khouly: none known

Figures

1
1
PRISMA study selection flow chart
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study
3
3
Risk of bias graph: review authors' judgements about each risk of bias item across studies
1.1
1.1. Analysis
Comparison 1: Immediate versus delayed treatment in women with increased CA125 levels, Outcome 1: Overall survival
2.1
2.1. Analysis
Comparison 2: Individualised nurse‐led follow‐up versus conventional medical follow‐up, Outcome 1: Quality of life (QLQ‐C30 score)
2.2
2.2. Analysis
Comparison 2: Individualised nurse‐led follow‐up versus conventional medical follow‐up, Outcome 2: Quality of life (QLQ‐Ov28 score)
2.3
2.3. Analysis
Comparison 2: Individualised nurse‐led follow‐up versus conventional medical follow‐up, Outcome 3: Psychological effects (HADS)
2.4
2.4. Analysis
Comparison 2: Individualised nurse‐led follow‐up versus conventional medical follow‐up, Outcome 4: Cost analysis
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Lanceley 2017 {published data only}
    1. Lanceley A, Berzuini C, Burnell M, Gessler S, Morris S, Ryan A, et al. Ovarian cancer follow-up: a preliminary comparison of 2 approaches. International Journal of Gynecological Cancer 2017;27(1):59-68. [DOI: 10.1097/IGC.0000000000000877] - DOI - PubMed
Rustin 2010 {published data only}
    1. Rustin GJ, Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al, on behalf of MRC and EORTC collaborators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010;376(9747):1155-63. - PubMed

References to studies excluded from this review

Esselen 2016 {published data only}
    1. Esselen KM, Cronin AM, Bixel K, Bookman MA, Burger RA, Cohn DE, et al. Use of CA-125 tests and computed tomographic scans for surveillance in ovarian cancer. JAMA Oncology 2016;2(11):1427-33. - PMC - PubMed
Esselen 2017 {published data only}
    1. Esselen KM, Cronin AM, Bixel K, Bookman MA, Burger RA, Cohn DE, et al. Use of CA-125 tests and computed tomographic scans for surveillance in ovarian cancer. Obstetrical & Gynecological survey 2017;71(11):660-1. [DOI: 10.1097/OGX.0000000000000377] - DOI - PMC - PubMed
Frangou 2021 {published data only}
    1. Frangou E, Bertelli G, Love S, Mackean MJ, Glasspool RM, Fotopoulou C, et al. OVPSYCH2: a randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer. Gynecologic Oncology 2021;162(2):431-9. [DOI: 10.1016/j.ygyno.2021.05.024] - DOI - PubMed
ISRCTN45565436 {published data only}
    1. ISRCTN45565436. A trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT-G). www.isrctn.com/ISRCTN45565436?q=ISRCTN45565436 (first registered 23 June 2015).
Juraskova 2017 {published data only}
    1. Juraskova I, Fisher A, Bonner C, Carter J. A randomised controlled trial of a treatment decision-aid for asymptomatic women with rising CA-125 after successful first-line therapy for ovarian cancer. Asia-Pacific Journal of Clinical Oncology 2017;13(4):65. [DOI: 10.1111/ajco.12798] - DOI
Le 2016 {published data only}
    1. Le T, Kennedy EB, Dodge J, Elit L. Follow-up of patients who are clinically disease-free after primary treatment for fallopian tube, primary peritoneal, or epithelial ovarian cancer: a program in evidence-based care guideline adaptation. Current Oncology 2016;23(5):343-50. [DOI: 10.3747/co.23.3042] - DOI - PMC - PubMed
Lindeman 2015 {published data only}
    1. Lindeman K, Kristensen G, Mirza MR, Davies L, Hilpert F, Romero I, et al. Computed tomography is more sensitive than CA-125 in detecting disease progression in patients with platinum-resistant ovarian cancer: Analysis of the AURELIA trial. International Journal of Gynecological Cancer 2015;25(Suppl 1):37-8. [DOI: 10.1097/01.IGC.0000473498.85773.6e] - DOI
Morrison 2017 {published data only}
    1. Morrison V, Spencer LH, Leeson S. Trial of optimal personalised care after treatment for gynaecological cancer (TOPCAT-G): a randomised feasibility trial. Psycho-Oncology 2017;26(2):3-4. [DOI: 10.1002/pon.4373] - DOI
Morrison 2018 {published data only}
    1. Morrison V, Spencer LH, Totton N, Pye K, Yeo ST, Butterworth C, et al. Trial of optimal personalised care after treatment - gynaecological cancer (TOPCAT-G): a randomized feasibility trial. International Journal of Gynecological Cancer 2018;28(2):401-11. [DOI: 10.1097/IGC.0000000000001179] - DOI - PubMed
NCT00002895 {published data only}
    1. NCT00002895. Early chemotherapy based on CA 125 level alone compared with delayed chemotherapy in treating patients with recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer. clinicaltrials.gov/show/NCT00002895 (first posted 27 January 2003).
NCT02298855 {published data only}
    1. NCT02298855. Individualised versus conventional medical follow-up for women after primary treatment for ovarian cancer. clinicaltrials.gov/show/NCT02298855 (first posted 21 November 2014).
NCT03838861 {published data only}
    1. NCT03838861. An individualised and patient-centred follow-up program for women with gynaecological cancer (NEMO). clinicaltrials.gov/ct2/show/record/NCT03838861 (first posted 10 February 2019).
Ngu 2020 {published data only}
    1. Ngu S-F, Wei N, Li J, Chu MMY, Tse KY, Ngan HYS, et al. Nurse-led follow-up in survivorship care of gynaecological malignancies – a randomised controlled trial. European Journal of Cancer Care 2020;29(6):e13325. [DOI: 10.1111/ecc.13325] - DOI - PubMed
Rustin 2011 {published and unpublished data}
    1. Rustin GJS. Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed. Annals of Oncology 2011;22(8):45-8. - PubMed

Additional references

Aaronson 1993
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institut 1993;85(5):365-76. - PubMed
Barzen 1990
    1. Barzen G, Cordes M, Langer M, Friedman W, Mayr AC, Felix R. Value of radioimmunoscintigraphy compared to computed tomography in the diagnosis and follow-up of primary ovarian carcinoma. RöFo:Fortschritte auf dem Gebiete der Röntgenstrahlen und derNuklearmedizin 1990;153(1):85-91. - PubMed
Beaver 2009
    1. Beaver K, Tysver-Robinson D, Campbell M, Twomey M, Williamson S, Hindley A, et al. Comparing hospital and telephone follow-up after treatment for breast cancer: randomised equivalence trial. BMJ 2009;338:a3147. - PMC - PubMed
Bradley 2000
    1. Bradley E, Pitts M, Redman C, Calvert E, Howells R, Wafai C. What are the factors associated with the follow-up preferences of women in long-term remission from gynaecological cancer? Journal of Obstetrics and Gynaecology 2000;20(4):408-11. - PubMed
Bristow 2009
    1. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecologic Oncology 2009;112(1):265-74. - PubMed
Bruzzone 1990
    1. Bruzzone M, Onetto M, Campora E, Chiara S, Oliva C, Guido T, et al. CA-125 monitoring in the management of ovarian cancer. Anticancer Research 1990;10(5A):1353-9. - PubMed
Capriglione 2017
    1. Capriglione S, Luvero D, Plotti F, Terranova C, Montera R, Scaletta G, et al. Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature. Medical Oncology 2017;34(9):164. - PubMed
Cerejeira 1989
    1. Cerejeira L, Pinto FMM, Otilia BMO, Moutinho J. Validity of gynaegnost in the follow-up of patients treated for ovarian cancer. Revue Française de Gynécologie et d'Obstétrique 1989;84(4):347-9. - PubMed
Chan 2008
    1. Chan KK, Tam KF, Tse KY, Ngan HY. The role of regular physical examination in the detection of ovarian cancer recurrence. Gynecologic Oncology 2008;110(2):158-61. - PubMed
Coleman 2020
    1. Coleman L, Newton C. Patient initiated follow up after gynaecological malignancy: national survey of current UK practice. European Journal of Obstetrics & Gynecology and Reproductive Biology 2020;248:193-7. - PubMed
Costanzo 2005
    1. Costanzo ES, Lutgendorf SK, Bradley SL, Rose SL, Anderson B. Cancer attributions, distress, and health practices among gynecologic cancer survivors. Psychosomatic Medicine 2005;67(6):972-80. - PubMed
Covidence [Computer program]
    1. Covidence. Version accessed January 2022. Melbourne, Australia: Veritas Health Innovation. Available at www.covidence.org.
Crombach 1985
    1. Crombach G, Zippel HH, Würz H. Clinical significance of cancer antigen 125 (CA 125) in ovarian cancer. Cancer Detection and Prevention 1985;8(1-2):135-9. - PubMed
CRUK 2022
    1. Cancer Research UK (CRUK). Ovarian cancer fact sheet. www.cancerresearchuk.org/health-professional/cancerstatistics/statistics... (accessed 27 July 2022).
Dachman 2001
    1. Dachman AH, Visweswaran A, Battula R, Jameel S, Waggoner SE. Role of chest CT in the follow-up of ovarian adenocarcinoma. American Journal of Roentgenology 2001;176(3):701-5. - PubMed
Engblom 1995
    1. Engblom PR, Grènman SE, Klemi PJ, Hirvonen TE, Rantanen VT, Salmi TA. The role of cul-de-sac aspiration cytology in the follow-up of ovarian cancer. Acta Oncologica (Stockholm Sweden) 1995;34(6):783-5. - PubMed
EUROCARE 2015
    1. Rossi S, Baili P, Capocaccia R, Caldora M, Carrani E, Minicozzi P, et al. The EUROCARE-5 study on cancer survival in Europe 1999-2007: database, quality checks and statistical analysis methods. European Journal of Cancer 2015;51(15):2104-19. - PubMed
Fayed 1998
    1. Fayed ST, Ahmad SM, Kassim SK, Khalifa A. The value of CA 125 and CA72-4 in management of patients with epithelial ovarian cancer. Disease Markers 1998;14(3):155-60. - PMC - PubMed
Fehm 2005
    1. Fehm T, Heller F, Krämer S, Jäger W, Gebauer G. Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients. Anticancer Research 2005;25(3A):1551-4. - PubMed
Feinberg 2022
    1. Feinberg J, Carthew K, Webster E, Chang K, McNeil N, Chi DS, et al. Ovarian cancer recurrence detection may not require in-person physical examination: an MSK team ovary study. International Journal of Gynecological Cancer 2022;32(2):159-64. - PMC - PubMed
Fidjeland 2018
    1. Fidjeland HL, Brekke M, Stokstad T, Vistad I. Gynecological cancer patients' attitudes toward follow-up care after cancer treatment: do preferences reflect patients' experience? A cross-sectional questionnaire study. Acta Obstetricia et Gynecologica Scandinavica 2018;97(11):1325-31. - PubMed
Fioretti 1992
    1. Fioretti P, Gadducci A, Ferdeghini M, Prontera C, Malagnino G, Facchini V, et al. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients. Gynecologic Oncology 1992;44(2):155-60. - PubMed
Fisken 1989
    1. Fisken J, Leonard RC, Shaw G, Bowman A, Roulston JE. Serum placental-like alkaline phosphatase PLAP: a novel combined enzyme linked immunoassay for monitoring ovarian cancer. Journal of Clinical Pathology 1989;42(1):40-5. - PMC - PubMed
Fotopoulou 2017
    1. Fotopoulou C, Hall M, Cruickshank D, Gabra H, Ganesan R, Hughes C, et al. British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. European Journal of Obstetrics and Gynecology 2017;213:129-39. - PubMed
Gadducci 1995
    1. Gadducci A, Marrai R, Baicchi U, Ferdeghini M, Fanucchi A, Facchini V, et al. The measurement of plasma D-dimer DD levels in the follow-up of patients with ovarian cancer. Anticancer Research 1995;15(6B):2683-6. - PubMed
Gadducci 1998
    1. Gadducci A, Ferdeghini M, Buttitta F, Cosio S, Fanucchi A, Annicchiarico C, et al. Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma. Anticancer Research 1998;18(5B):3763–5. - PubMed
Gadducci 2001
    1. Gadducci A, Ferdeghini M, Cosio S, Fanucchi A, Cristofani R, Genazzani AR. The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer. International Journal of Gynecological Cancer 2001;11(4):277-82. - PubMed
Gaducci 2007
    1. Gadducci A, Cosio S, Zola P, Landoni F, Maggino T, Sartori E. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. International Journal of Cancer 2007;17(1):21-31. - PubMed
García 2003
    1. García VMJ, Boán GJF, Villar LLM, Aramendía BJM, López GG, Richter EJA. F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125. Revista Espanola de Medicina Nuclear 2003;22(4):217-23. - PubMed
Garzetti 1991
    1. Garzetti GC, Di LRM, Ciavattini A, Pallotta MR, Marchegiani F, Valensise H, et al. Tumor markers in the early diagnosis of recurrence in gynecologic neoplasms: combined determination of CA-125, CA 15-3, CA 724, SCC, 90 K. Annali di Ostetricia, Ginecologia, Medicina Perinatale 1991;112(5):320-3. - PubMed
Giannopoulou 2017
    1. Giannopoulou L, Kasimir-Bauer S, Lianidou E. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA. Clinical Chemistry and Laboratory Medicine 2017;56(2):186-97. - PubMed
GLOBOCAN 2020
    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 2021;71:209-49. - PubMed
Goonewardene 2007
    1. Goonewardene TI, Hall MR, Rustin GJS. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncology 2007;8(9):813-21. - PubMed
Grabiec 2006
    1. Grabiec M, Walentowicz M, Nowicki P. The value of FDG PET/CT, ultrasound and CT in diagnosing recurrent ovarian carcinoma. Ginekologia Polska 2006;77(10):746-52. - PubMed
GRADE Working Group
    1. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490-4. - PMC - PubMed
GRADEpro GDT [Computer program]
    1. GRADEpro GDT. Version accessed January 2022. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.
Greimel 2003
    1. Greimel E, Bottomley A, Cull A, Waldenstrom AC, Arraras J, Chauvenet L, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. European Journal of Cancer 2003;39(10):1402-8. - PubMed
Greimel 2011
    1. Greimel E, Lahousen M, Dorfer M, Lambauer M, Lang U. Patients' view of routine follow-up after gynecological cancer treatment. European Journal of Obstetrics & Gynecology and Reproductive Biology 2011;159(1):180-3. - PubMed
Gritzmann 1986
    1. Gritzmann N, Karnel F, Imhof H, Wagner G, Müller TE, Dittrich C. Abdominal computerized tomography in the after-care of ovarian cancers. Digitale Bilddiagnostik 1986;6(4):171-5. - PubMed
Grunfeld 1996
    1. Grunfeld E, Mant D, Yudkin P, Adewuyi-Dalton R, Cole D, Stewart J, et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ 1996;313:665-9. - PMC - PubMed
Harter 2021
    1. Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, et al. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. New England Journal of Medicine 2021;385(23):2123-31. - PubMed
Hauth 2005
    1. Hauth EAM, Antoch G, Stattaus J, Kuehl H, Veit P, Bockisch A, et al. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. European Journal of Radiology 2005;56(2):263-8. - PubMed
Hernádi 1992
    1. Hernádi Z, Molnár V, Juhász B, Pólka R, Margitai B. Predictive value of the tumor marker combination CA-125 and beta-2- microglobulin in ovarian cancer. Zentralblatt für Gynäkologie 1992;114(1):6-9. - PubMed
Hetzel 1983
    1. Hetzel H, Bichler A, Fuchs D, Hausen A, Reibnegger G, Wachter H. Significance of urinary neopterine in gynecological oncology: follow-up of patients with ovarian cancer. Cancer Detection and Prevention 1983;6(1-2):263-6. - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Available from training.cochrane.org/handbook#previous-versions.
Higgins 2022
    1. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
Hising 1991
    1. Hising C, Anjegård IM, Einhorn N. Clinical relevance of the CA 125 assay in monitoring of ovarian cancer patients. American Journal of Clinical Oncology 1991;14(2):111-4. - PubMed
IARC 2021
    1. Bray F, Colombet M, Mery L, Piñeros M, Znaor A, Zanetti R, et al. Cancer incidence in five continents. In: IARC Scientific Publication No 166. Vol. XI. Lyon, France: IARC Scientific Publication, 2021.
Inoue 1985
    1. Inoue M, Fujita Y, Abe Y, Inoue Y, Ueda G, Tanizawa O, et al. Tissue polypeptide antigen as a tumor marker for gynecologic malignancies. Nippon Sanka Fujinka Gakkai Zasshi 1985;37(9):1799-805. - PubMed
Iwanari 1989
    1. Iwanari O, Miyako J, Date Y, Moriyama M, Yoshino N, Kijima S, et al. Diagnosis and follow-up of ovarian cancer by a combination assay of serum sialyl SSEA-1 antigen and CA125 levels. Nippon Gan Chiryo Gakkai Shi 1989;24(6):1256-60. - PubMed
Javitt 2007
    1. Javitt MC. ACR appropriateness criteria on staging and follow-up of ovarian cancer. Journal of the American College of Radiology 2007;4(9):586-9. - PubMed
Jeppesen 2018
    1. Jeppesen MM, Jensen PT, Hansen DG, Christensen RD, Mogensen O. Patient-initiated follow-up affects fear of recurrence and healthcare use: a randomised trial in early-stage endometrial cancer. British Journal of Obstetrics and Gynaecology 2018;125(13):1705-14. - PubMed
Kaesemann 1986
    1. Kaesemann H, Caffier H, Hoffmann FJ, Crombach G, Würz H, Kreienberg R, et al. Monoclonal antibodies in the diagnosis and follow-up of ovarian cancer CA 125 as a tumor marker A cooperative study of the Gynecologic Tumor Marker Group GTMG. Klinische Wochenschrift 1986;64(17):781-5. - PubMed
Kerr‐Wilson 1995
    1. Kerr‐Wilson RH, McCrum A. Follow‐up of patients with gynaecological cancer. Australian and New Zealand Journal of Obstetrics and Gynaecology 1995;35(3):298-9. - PubMed
Kew 2005
    1. Kew FM, Roberts AP, Cruickshank DJ. The role of routine follow-up after gynecological malignancy. International Journal of Gynecological Cancer 2005;15(3):413-9. - PubMed
Kew 2006
    1. Kew FM, Cruickshank DJ. Routine follow up after treatment for a gynaecological cancer: a survey of practice. International Journal of Gynecological Cancer 2006;16:380-4. - PubMed
Khan 1986
    1. Khan O, Cosgrove DO, Fried AM, Savage PE. Ovarian carcinoma follow-up: US versus laparotomy. Radiology 1986;159(1):111-3. - PubMed
Khoo 1974
    1. Khoo SK, Mackay EV. Carcinoembryonic antigen by radioimmunoassay in the detection of recurrence during long-term follow-up of female genital cancer. Cancer 1974;34(3):542-8. - PubMed
Khoo 1979
    1. Khoo SK, Whitaker S, Jones I, Mackay E. Predictive value of serial carcinoembryonic antigen levels in long-term follow-up of ovarian cancer. Cancer 1979;43(6):2471-8. - PubMed
Kim 2007
    1. Kim CK, Park BK, Choi JY, Kim B-G, Han H. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT. Journal of Computer Assisted Tomography 2007;31(6):868-75. - PubMed
Kitajima 2008
    1. Kitajima K, Murakami K, Yamasaki E, Domeki Y, Kaji Y, Fukasawa I, et al. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. European Journal of Nuclear Medicine & Molecular Imaging 2008;35(8):1439-48. - PubMed
Kobayashi 1989
    1. Kobayashi H. Clinical usefulness of serum sialyl Lex-i measurement in patients with ovarian cancer. Nippon Sanka Fujinka Gakkai Zasshi 1989;41(1):15-9. - PubMed
Kubik 2000
    1. Kubik HRA, Dörffler W, von SGK, Marincek B, Köchli OR, Seifert B, et al. Value of 18F-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. European Radiology 2000;10(5):761-7. - PubMed
Lahousen 1987
    1. Lahousen M, Stettner H, Pickel H, Urdl W, Pürstner P. The predictive value of a combination of tumor markers in monitoring patients with ovarian cancer. Cancer 1987;60(9):2228-32. - PubMed
Langendam 2013
    1. Langendam MW, Akl EA, Dahm P, Glasziou, P, Guyatt G, Schünemann HJ. Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews 2013;2:81-90. - PMC - PubMed
Ledermann 2013
    1. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C, ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2013;24 Suppl 6:vi24-32. - PubMed
Leeson 2013
    1. Leeson S, Stuart N, Sylvestre Y, Hall L, Whitaker R. Gynaecological cancer follow-up: national survey of current practice in the UK. BMJ Open 2013;3:e002859. - PMC - PubMed
Lenehan 1986
    1. Lenehan PM, Dembo AJ, Miceli PN, Malkin DG, Malkin A. Clinical correlations of carcinoembryonic antigen in post-operative patients with epithelial ovarian cancer. Tumour Biology : The Journal of The International Society for Onco-developmental Biology and Medicine 1986;7(5-6):389-405. - PubMed
Lenhard 2008
    1. Lenhard MS, Burges A, Johnson TR, Stieber P, Kumper C, Ditsch N, et al. PET-CT in recurrent ovarian cancer: impact on treatment planning. Anticancer Research 2008;28(4C):2303-8. [PMID: ] - PubMed
Low 1999
    1. Low RN, Saleh F, Song SY, Shiftan TA, Barone RM, Lacey CG, et al. Treated ovarian cancer: comparison of MR imaging with serum CA-125 level and physical examination – a longitudinal study. Radiology 1999;211(2):519-28. - PubMed
Mangili 2007
    1. Mangili G, Picchio M, Sironi S, Vigano R, Rabaiotti E, Bornaghi D, et al. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. European Journal of Nuclear Medicine & Molecular Imaging 2007;34(5):658-66. - PubMed
Meader 2014
    1. Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews 2014;3:82. - PMC - PubMed
Moore 2002
    1. Moore S, Corner J, Haviland J, Wells M, Salmon E, Normand C, et al. Nurse led follow-up and conventional medical follow-up in management of patients with lung cancer: randomised trial. BMJ 2002;325:1145. - PMC - PubMed
Musoro 2020
    1. Musoro JZ, Coens C, Greimel E, King MT, Sprangers MAG, Nordin A, et al. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer. Gynecologic Oncology 2020;159(2):515-21. - PubMed
Nakamoto 2001
    1. Nakamoto Y, Saga T, Ishimori T, Mamede M, Togashi K, Higuchi T, et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. American Journal of Roentgenology 2001;176(6):1449-54. - PubMed
Newton 2020
    1. Nwton C, Nordin A, Roland P, Ind T, Larsen-Disney P, Martin-Hirsch P, et al. British Gynaecological Cancer Society recommendations and guidance on patient-initiated follow-up (PIFU). International Journal of Gynecological Cancer 2020;0:1-6. [DOI: 10.1136/ijgc-2019-001176] - DOI - PubMed
Oehler 1999
    1. Oehler MK, Sütterlin M, Caffier H. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer. Anticancer Research 1999;19(4A):2513-8. - PubMed
Okai 1992
    1. Okai T, Kagawa H, Masuda H, Kozuma S, Mizuno M. Assessment of ovarian tumors by transvaginal scanning and clinical significance of ultrasonic examination in postoperative follow up. Rinsho Byori. The Japanese Journal of Clinical Pathology 1992;40(4):363-8. - PubMed
Olaitan 2001
    1. Olaitan A, Murdoch J, Anderson R, James J, Graham J, Barley V. A critical evaluation of current protocols for the follow-up of women treated for gynecological malignancies: a pilot study. International Journal of Gynecologic Cancer 2001;11(5):349-53. - PubMed
Palmer 2006
    1. Palmer C, Pratt J, Basu B, Earl H. A study to evaluate the use of CA125 in ovarian cancer follow-up: a change in practice led by patient preference. Gynecologic Oncology 2006;101(1):4-11. - PubMed
Parker 2006
    1. Parker PA, Kudelka A, Basen-Engquist K, Kavanagh J, Moor J, Cohen L. The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer. Gynecologic Oncology 2006;100(3):495-500. [PMID: ] - PubMed
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998 Dec 30;17(24):2815-34; Erratum in Statistics in Medicine 2004 Jun 15;23(11):1817. - PubMed
Poveda 2021
    1. Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology 2021;22(5):620-31. - PubMed
Prayer 1993
    1. Prayer L, Kainz C, Kramer J, Stiglbauer R, Schurawitzki H, Baldt M, et al. CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer. Journal of Computer Assisted Tomography 1993;17(4):626-32. - PubMed
Reid 2011
    1. Reid A, Ercolano E, Schwartz P, McCorkle R. The management of anxiety and knowledge of serum CA-125 after an ovarian cancer diagnosis. Clinical Journal of Oncology Nursing 2011;15(6):625-32. - PubMed
Renehan 2002
    1. Renehan AG, Egger M, Saunders MP, O'Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 2002;324:813. - PMC - PubMed
Renehan 2005
    1. Renehan AG, Egger M, Saunders MP, O'Dwyer ST. Mechanisms of improved survival from intensive follow up in colorectal cancer: a hypothesis. British Journal of Cancer 2005;92(3):430-3. - PMC - PubMed
RevMan 2020 [Computer program]
    1. Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.
RevMan Web 2023 [Computer program]
    1. Review Manager Web (RevMan Web). Version 5.6.0. The Cochrane Collaboration, 2023. Available at revman.cochrane.org.
Roberts 2009
    1. Roberts K, Clarke C. Future disorientation following gynaecological cancer: women’s conceptualisation of risk after a life-threatening illness. Health, Risk & Society 2009;11(4):353–66.
Rohr 2016
    1. Rohr I, Zeillinger R, Heinrich M, Concin N, Vergote I, Nassir M, et al. Role of IGF-I in primary ovarian cancer - a study of the OVCAD European Consortium. Anticancer Research 2016;36(3):1015–22. - PubMed
Rustin 1996a
    1. Rustin G, Tuxen M. Use of CA 125 in follow-up of ovarian cancer. Lancet 1996;348(9021):191-2. - PubMed
Sandell 2022
    1. Sandell T, Schütze H. Factors influencing the translation of shared cancer follow-up care into clinical practice: a systematic review. BMJ Open 2022;12(8):e055460. - PMC - PubMed
Schneider 2020
    1. Schneider B, Ismaila N, Aerts J, Chiles C, Daly M, Detterbeck F, et al. Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline. Journal of Clinical Oncology 2020;38(7):753-66. - PubMed
Schorge 2004
    1. Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, et al. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2004;10(10):3474-8. - PubMed
Schünemann 2022
    1. Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Available from www.training.cochrane.org/handbook.
Sella 2001
    1. Sella T, Rosenbaum E, Edelmann DZ, Agid R, Bloom AI, Libson E. Value of chest CT scans in routine ovarian carcinoma follow-up. American Journal of Roentgenology 2001;177(4):857-9. - PubMed
Shimizu 1986
    1. Shimizu Y, Akagaki E, Hirota K, Kono M, Miura S, Okudaira Y, et al. Significance of immunosuppressive acidic protein in the diagnosis and follow-up of patients with ovarian cancer, in particular as a marker for chemotherapeutic effects. Nippon Sanka Fujinka Gakkai Zasshi 1986;38(4):554-60. - PubMed
Shinozuka 1994
    1. Shinozuka T, Miyamoto T, Hirazono K, Ebisawa K, Murakami M, Kuroshima Y, et al. Follow-up laparoscopy in patients with ovarian cancer. The Tokai Journal of Experimental and Clinical Medicine 1994;19(1-2):53-9. - PubMed
Siegel 2023
    1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics. CA: A Cancer Journal for Clinicians 2023;73(1):17-48. - PubMed
Sliutz 1995
    1. Sliutz G, Tempfer C, Kainz C, Mustafa G, Gitsch G, Koelbl H, et al. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer. Anticancer Research 1995;15(3):1127-9. - PubMed
Sugiyama 1996
    1. Sugiyama Y, Shimizu Y, Umezawa S, Yamauchi K, Hasumi K. Feasibility of peritoneal washing cytology through the totally implanted reservoir for early detection of peritoneal recurrence of ovarian cancer. Nippon Sanka Fujinka Gakkai Zasshi 1996;48(3):213-9. - PubMed
Tattersall 2022
    1. Tattersall A, Ryan N, Wiggans AJ, Rogozińska E, Morrison J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database of Systematic Reviews 2022, Issue 2. Art. No: CD007929. [DOI: 10.1002/14651858.CD007929.pub4] - DOI - PMC - PubMed
Tempfer 1998
    1. Tempfer C, Hefler L, Haeusler G, Reinthaller A, Koelbl H, Zeisler H, et al. Tissue polypeptide specific antigen in the follow-up of ovarian and cervical cancer patients. International Journal of Cancer. Journal International du Cancer 1998;79(3):241-4. - PubMed
Testa 2002
    1. Testa AC, Ciampelli M, Mastromarino C, Lopez R, Zannoni GF, Mancuso S, et al. Detection of central pelvic recurrent disease with transvaginal color Doppler ultrasound in women treated for gynecological malignancy. Ultrasound in Obstetrics & Gynecology 2002;19(5):490-5. - PubMed
Testa 2005
    1. Testa AC, Fruscella E, Ludovisi M, De Vincenzo R, Malaggese M, Corrado G, et al. The role of sonographic examination in the follow-up of gynecological neoplasms. Gynecologic Oncology 2005;99(3):696-703. - PubMed
Thrall 2007
    1. Thrall MM, DeLoia JA, Gallion H, Avril N. Clinical use of combined positron emission tomography and computed tomography FDG-PET/CT in recurrent ovarian cancer. Gynecologic Oncology 2007;105(1):17-22. - PubMed
Tierney 2007
    1. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16. - PMC - PubMed
Torizuka 2002
    1. Torizuka T, Nobezawa S, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy- D-glucose. European Journal of Nuclear Medicine and Molecular Imaging 2002;29(6):797-803. - PubMed
Trimble 1994
    1. Trimble EL. The NIH consensus conference on ovarian cancer: screening, treatment, and follow-up. Gynecologic Oncology 1994;55(3 pt2):S1-3. - PubMed
Tuxen 2002
    1. Tuxen MK, Sölétormos G, Dombernowsky P. Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up. Scandinavian Journal of Clinical and Laboratory Investigation 2002;62(3):177-88. - PubMed
VillaSanta 1980
    1. VillaSanta U, Jovanovski D. Follow-up study of ovarian carcinoma by cytology of cul-de-sac aspirates. Gynecologic Oncology 1980;10(1):58-62. - PubMed
Vinokurov 1992
    1. Vinokurov VL, Dudarev AL, Jurkova LE, Lapchenkov VI, Barbanel EJ. Tumor marker CA 125 in diagnosis, monitoring management and follow-up of patients with ovarian tumors. European Journal of Gynaecological Oncology 1992;13(2):205-8. - PubMed
Von Georgi 2004
    1. Von Georgi R, Schubert K, Grant P, Münsted K. Post-therapy surveillance and after-care in ovarian cancer. European Journal of Obstetrics & Gynecology and Reproductive Biology 2004;114:228-33. - PubMed
Vuento 2007
    1. Vuento M, Salmi T, Klemi P, Grénman S. Ultrasonographic-guided pervaginal cul-de-sac cytology in the follow-up of ovarian carcinoma. Anticancer Research 2007;27(2):1015-8. - PubMed
Zakrzewska 2000
    1. Zakrzewska I, Borawska R. The value of serum tissue polypeptide specific antigen TPS concentration in therapeutic monitoring of patients with epithelial malignant ovarian neoplasms [Wartość oznaczania stezenia specyficznego polipeptydowego antygenu TPS w surowicy w monitorowaniu leczenia chorych na nabłonkowe złośliwe nowotwory jajnika]. Ginekologia Polska 2000;71(12):1523–31. - PubMed
Zhu 2002
    1. Zhu X, Shen K, Lang J, Wu M, Huang H, Pan L. Role of positron emission tomography in detecting recurrent epithelial ovarian carcinoma. Zhonghua Fu Chan Ke za Zhi 2002;37(6):356-8. - PubMed
Zigmond 1983
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica 1983;67(6):361-70. - PubMed
Zimny 2001
    1. Zimny M, Siggelkow W, Schröder W, Nowak B, Biemann S, Rath W, et al. 2-Fluorine-18-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecologic Oncology 2001;83(2):310-5. - PubMed

References to other published versions of this review

Clarke 2014
    1. Clarke T, Galaal K, Bryant A, Naik R. Evaluation of follow‐up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Cochrane Database of Systematic Reviews 2014, Issue 9. Art. No: CD006119. [DOI: 10.1002/14651858.CD006119.pub3] - DOI - PMC - PubMed
Kew 2011
    1. Kew F, Galaal K, Bryant A, Naik R. Evaluation of follow‐up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Cochrane Database of Systematic Reviews 2011, Issue 6. Art. No: CD006119. [DOI: 10.1002/14651858.CD006119.pub2] - DOI - PMC - PubMed
Naik 2006
    1. Naik R, Kew F, Das N, Deane K. Evaluation of follow‐up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No: CD006119. [DOI: 10.1002/14651858.CD006119] - DOI - PMC - PubMed

Publication types